IP Library Granted Patent US 10,632,156
Granted Patent B2
US 10,632,156 · App. 15/129,611 · Granted Apr 28, 2020

Preparation of small colony variants of therapeutic bacteria

Inventors: Steven R. Watt (Windsor, WI); Caleb W. Dorsey (Verona, WI); Joshua A. Smith (New Glarus, WI)
Assignee: Atterx Biotherapeutics, Inc.
A61K35/741A61K9/0034A61K35/74A61L29/005A61L29/085A61L29/145A61M25/0045C12N1/20C12N1/32C12N1/38A61L2400/10A61M25/0017A61M2025/0046C12N2500/05C12N2500/14C12N2500/16C12N2500/20C12N2500/22C12N2500/24C12N2500/32C12N2500/34C12N2500/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,632,156
App. No.
15/129,611
Granted
Apr 28, 2020
Kind
B2
Abstract

The invention relates to methods of differentiation, isolation, propagation, and storage of small colony variants (SCVs) of E. coli , preferably E. coli 83972 or E. coli HU2117, or modified or variant forms thereof, and methods for using the prepared SCV bacteria to establish probiotic biofilms in treated subjects and/or on treated medical devices.

Claims (148)

1. A method of culturing probiotic bacteria, comprising:

a) isolating an E. coli small colony variant (SCV) bacterium to form a preparation of SCV E. coli bacterial cells that is free of large colony variant (LCV) E. coli bacterial cells, wherein said E. coli SCV bacterium is selected from E. coli 83972 and E. coli HU2117, or a variant or derivative thereof;

b) inoculating a liquid growth medium with said preparation of SCV E. coli bacterial cells, wherein said liquid growth medium is a supplemented minimal medium comprising:

i) a buffer solution;

ii) a sugar or sugar alcohol; and

iii) cysteine, methionine, serine, and lysine,

wherein said liquid growth medium does not comprise added adenine, cytosine, guanine, uracil, yeast extract, or an enzymatic digest of complex protein;

c) incubating said liquid growth medium inoculated with said preparation of SCV E. coli bacterial cells to produce a liquid culture of SCV E. coli bacterial cells, wherein fewer than 50% of E. coli bacterial cells in the liquid culture are LCV E. coli bacterial cells.

2. The method of claim 1 , wherein said sugar or sugar alcohol comprises glycerol.

3. The method of claim 2 , wherein said sugar or sugar alcohol consists of glycerol as the sole added carbon source in said liquid growth medium.

4. The method of claim 1 , wherein in said liquid culture of SCV E. coli bacterial cells, fewer than 30% of E. coli bacterial cells in the liquid culture are LCV E. coli bacterial cells.

5. The method of claim 1 , wherein said liquid culture of SCV E. coli bacterial cells is free of LCV E. coli bacterial cells.

6. The method of claim 1 wherein said isolating comprises isolating an SCV bacterium from urine.

7. The method of claim 1 , wherein said isolating comprises growing an SCV bacterium in urine, wherein said urine comprises one or more of natural urine and synthetic urine.

8. The method of claim 1 , wherein said isolating comprises growing said SCV bacterium on a solid culture medium.

9. The method of claim 8 , wherein said solid culture medium is MacConkey's agar.

10. The method of claim 1 , wherein said buffer solution is a 3-(N-morpholino)propanesulfonic acid (MOPS) buffer solution.

11. The method of claim 10 , wherein said MOPS buffer is MOPS/tricine.

12. The method of claim 1 , wherein said liquid growth medium further comprises one or more amino acids selected from asparagine, aspartic acid, glycine, phenylalanine, and tryptophan.

13. The method of claim 1 , wherein said liquid growth medium comprises one or more of ferrous sulfate, ammonium chloride, potassium sulfate, calcium chloride, magnesium chloride, and sodium chloride.

14. The method of claim 1 , wherein said liquid growth medium further comprises one or more of ammonium molybdate, boric acid, cobalt chloride, cupric sulfate, manganese chloride and zinc sulfate.

15. The method of claim 1 , wherein said liquid growth medium consists essentially of:

MOPS

40

mM

(3-(N-morpholino)-

4

mM

propanesulfonic acid)

Tricine

Iron Sulfate

10

μM

Ammonium Chloride

9.5

mM

Potassium Sulfate

276

μM

Calcium Chloride Monohydrate

0.5

μM

Magnesium Chloride

525

μM

Sodium Chloride

50

mM

Ammonium Molybdate

2.92 × 10 −9

M

Boric Acid

4 × 10 −7

M

Cobalt Chloride

3.02 × 10 −8

M

Cupric Sulfate

9.62 × 10 −9

M

Manganese Chloride

8.08 × 10 −8

M

Zinc Sulfate

9.74 × 10 −9

M

Potassium Phosphate, Dibasic

1.32

mM

Alanine

0.798

mM

Arginine HCl

5.2

mM

Asparagine

0.4

mM

Aspartic Acid, Potassium Salt

0.4

mM

Cysteine Monohydrate HCl

0.1

mM

Glutamic Acid, Potassium Salt

0.7

mM

Glutamine

0.6

mM

Glycine

0.8

mM

Histidine monohydrate HCl

0.2

mM

Isoleucine

0.4

mM

Leucine

0.8

mM

Lysine DiHydrochloride

0.4

mM

Methionine

0.2

mM

Phenylalanine

0.4

mM

Proline

0.4

mM

Serine

10.0

mM

Threonine

0.4

mM

Tryptophane

0.1

mM

Tyrosine

0.2

mM

Valine

0.6

mM

Thiamine HCl

0.01

mM

Calcium Pantothenate

0.01

mM

ρ-aminobenzoic acid

0.01

mM

ρ-hydroxybenzoic acid

0.01

mM

2,3-dihydroxybenzoic acid

0.01

mM

Glycerol

0.4%

(w/v)

Water

Assignments (2)
CHANGE OF NAME Recorded May 30, 2019
From: CONJUGON, INC.
To: ATTERX BIOTHERAPEUTICS, INC.
Reel/Frame 050313/0288 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2016
From: WATT, STEVEN R.; DORSEY, CALEB W.; SMITH, JOSHUA A.
To: CONJUGON, INC.
Reel/Frame 039867/0915 →
Continuity (2)
Provisional Application 61971913 · Mar 28, 2014
Related Publication 20170173087A1 · Jun 22, 2017